NxStage Medical Reports Fourth Quarter and Full Year 20...(ding estimated non-cash stock-based stoc...),Health

For the full year 2008, NxStage expects revenue to be in the range of $130 million to $140 million. The Company expects a net loss in the range of $52 million to $56 million or ($1.41) to ($1.52) per share for the full year 2008, including estimated non-cash stock-based stock compensation charges of $6.0 million to 7.0 million and amortization of acquisition intangibles of $3.0 million. The Company expects to end the year with 3,700 to 4,100 patients at approximately 420 to 450 centers offering therapy with the NxStage System One.

Conference Call

NxStage will host a conference call at 9:00 a.m. Eastern Time on February 12, 2008 to discuss its fourth quarter and year end 2007 financial results. To listen to the conference call, please dial (888) 713-4214 for domestic callers and (617) 213-4866 for international callers. The passcode is 20821233. A replay of the conference call will be available two hours after the start of the call through February 26, 2008 by dialing 888-286-8010 (domestic) and 617- 801-6888 (international), passcode 30075901. An online archive of the conference call will also be available by accessing the Investor Information section of the Company's website at http://www.nxstage.com.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment
'/>"/>